China based BGI Genomics. Co. Ltd. and its US subsidiary BGI Americas Corp. have announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its RT-PCR kit for detecting SARS-CoV-2.
BGI’s highly sensitive test can return results within three hours. It is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19 disease, in bronchoalveolar lavage fluid (BALF) and throat swabs.
“The authorization of our diagnostic test for COVID-19 in the US will provide high-quality, high-volume testing capabilities to the US, and enable medical professionals to respond quickly to diagnose patients, preventing further spread of infection,” said Ye Yin, CEO of BGI Genomics.
Advantages of BGI’s test include:
High sensitivity– Limit of Detection at 100 copies/mL in BALF and 150 copies/mL in throat swabs
High specificity – No cross-reactivity with 54 human respiratory pathogens
Fast TAT – Sample to result in 3 hours
Ease of use – All inclusive with pre-mixed reaction reagents
Easy interpretation – Analysis of one target with well-defined controls
